Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...

Pharmacogenetics of Drug Metabolism: Overview

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...

Pharmacogenomics: Identification of New Drug Targets

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...

Principles of Pharmacogenetics: Types of Genetic Variants

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Biocompatibility and dimensional stability through the use of 3D-printed scaffolds made by polycaprolactone and bioglass-7: An in vitro and in vivo study.

Clinical implant dentistry and related research·2024

Same author

Release of P-TEFb from the Super Elongation Complex promotes HIV-1 latency reversal.

PLoS pathogens·2024

Same author

Erratum to "Vertical augmentation of a severely atrophied posterior mandibular alveolar ridge for a dental implant using a patient-specific 3D printed PCL/BGS7 scaffold: A technical note" [J Stomatol Oral Maxillofac Surg 124 (2022) 101297].

Journal of stomatology, oral and maxillofacial surgery·2024

Same author

Glutamine-mediated epigenetic regulation of cFLIP underlies resistance to TRAIL in pancreatic cancer.

Experimental & molecular medicine·2024

Same author

Correction: Autotaxin inhibition attenuates the aortic valve calcification by suppressing inflammation-driven fibro-calcific remodeling of valvular interstitial cells.

BMC medicine·2024

Same author

Comparative Pharmacokinetics of Gentamicin C<sub>1</sub>, C<sub>1a</sub> and C<sub>2</sub> in Healthy and Infected Piglets.

Antibiotics (Basel, Switzerland)·2024

Search research articles

Related Experiment Video

Updated: Jun 28, 2026

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures

Published on: March 28, 2017

Auto-interpreter for CYP2D6 SNaPshot genotyping.

Sungmoon Ong¹, Hye-Eun Jeong, Sang Seop Lee

¹Inje University College of Medicine, Busan, Korea.

AMIA ... Annual Symposium Proceedings. AMIA Symposium

|November 13, 2008

Summary

CYP2D6 genotyping with the SNaPshot method is clinically useful but difficult to interpret. An automated interpreter was developed, showing good concordance with experts, to accelerate clinical adoption.

More Related Videos

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

Related Experiment Videos

Last Updated: Jun 28, 2026

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures

Published on: March 28, 2017

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

Area of Science:

Pharmacogenomics
Clinical Diagnostics
Bioinformatics

Background:

CYP2D6 genotyping is crucial for personalized medicine, guiding drug selection and dosage.
The SNaPshot method offers a practical approach for CYP2D6 genotyping.
Interpreting raw SNaPshot data for CYP2D6 genotyping requires specialized expertise, posing a barrier to widespread clinical use.

Purpose of the Study:

To develop and validate an automated interpretation tool for CYP2D6 genotyping data obtained via the SNaPshot method.
To simplify and standardize the process of genotype determination from SNaPshot results.
To facilitate the clinical implementation of CYP2D6 genotyping.

Main Methods:

Development of a SNaPshot auto-interpreter algorithm.
Testing the auto-interpreter on raw CYP2D6 genotyping data.
Comparison of auto-interpreter results with expert genotype interpretation.

Main Results:

The SNaPshot auto-interpreter successfully converted raw data into interpretable CYP2D6 genotypes.
The auto-interpreter demonstrated high concordance with genotype assignments made by experienced clinical experts.
Validation confirmed the reliability and accuracy of the automated interpretation.

Conclusions:

The validated SNaPshot auto-interpreter effectively simplifies CYP2D6 genotype interpretation.
This tool has the potential to significantly accelerate the clinical application of CYP2D6 genotyping.
Automated interpretation enhances the accessibility and efficiency of pharmacogenetic testing.